增量成本效果比(ICER)的决策含义辨析  

Discrimination in Decision Making Implications of Incremental Cost Effectiveness Ratio(ICER)

作　　者：陶立波 刘畅 Tao Libo;Liu Chang(Center for Health Policy and Technology Assessment,Department of Medicine,Peking University,Beijing,100191)

机构地区：[1]北京大学医学部卫生政策与技术评估中心,北京100191

出　　处：《中国医疗保险》2021年第4期66-68,共3页China Health Insurance

摘　　要：增量成本效果比是卫生经济学评价中重要的评价指标。本文分析了增量成本效果比的定义、内涵和决策意义,并比较了该指标与平均成本效果比的差异,认为增量成本效果比是更优的分析指标,建议在相关决策工作中深入理解其含义并加以恰当应用。Incremental Cost Effectiveness Ratio(ICER)is an important indicator in health economics evaluation.In this paper,we analyzed the defi nition,content and application of ICER,demonstrated the diff erences between ICER and cost eff ectiveness ratio(CER),and found out ICER was better.ICER should be appropriately understood and applied by decision makers.

关 键 词：卫生经济学评价 增量成本效果比 决策 

分 类 号：F840.684[经济管理—保险] C913.7[社会学]